This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-15. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
In 1939, the Soviet Union and Nazi Germany agreed to the Treaty of Non-aggression between Germany and the Union of Soviet Socialist Republics (Molotov–Ribbentrop Pact, 23 August 1939) and to jointly invade and partition Poland, by way of which Nazi Germany started the Second World War (1 September 1939). In the 1941–1942 period of the Great Patriotic War, the German invasion of the Soviet Union (Operation Barbarossa, 22 June 1941) was ineffectively opposed by the Red Army, who were poorly led, ill-trained and under-equipped. As a result, they fought poorly and suffered great losses of soldiers (killed, wounded and captured). The weakness of the Red Army was partly consequence of the Great Purge (1936–1938) of senior officers and career soldiers whom Stalin considered politically unreliable. Strategically, the Wehrmacht's extensive and effective attack threatened the territorial integrity of the Soviet Union and the political integrity of Stalin's model of a communist state, when the Nazis were initially welcomed as liberators by the anti-communist and nationalist populations in the Byelorussian Soviet Socialist Republic, the Georgian Soviet Socialist Republic and the Ukrainian Soviet Socialist Republic. The anti-Soviet nationalists' collaboration with the Nazi's lasted until the Schutzstaffel and the Einsatzgruppen began their Lebensraum killings of the Jewish populations, the local communists, the civil and community leaders—the Holocaust meant to realise the Nazi German colonisation of Bolshevik Russia.
=== Iron export === A different perspective on Alzheimer's is revealed by a mouse study that has found that APP possesses ferroxidase activity similar to ceruloplasmin, facilitating iron export through interaction with ferroportin; it seems that this activity is blocked by zinc trapped by accumulated Aβ in Alzheimer's. It has been shown that a single nucleotide polymorphism in the 5'UTR of APP mRNA can disrupt its translation. The hypothesis that APP has ferroxidase activity in its E2 domain and facilitates export of Fe(II) is possibly incorrect since the proposed ferroxidase site of APP located in the E2 domain does not have ferroxidase activity. As APP does not possess ferroxidase activity within its E2 domain, the mechanism of APP-modulated iron efflux from ferroportin has come under scrutiny. One model suggests that APP acts to stabilize the iron efflux protein ferroportin in the plasma membrane of cells thereby increasing the total number of ferroportin molecules at the membrane. These iron-transporters can then be activated by known mammalian ferroxidases (i.e. ceruloplasmin or hephaestin).
== Properties == The properties of a material in nanoparticle form are unusually different from those of the bulk one even when divided into micrometer-size particles. Many of them arise from spatial confinement of sub-atomic particles (i.e. electrons, protons, photons) and electric fields around these particles. The large surface to volume ratio is also significant factor at this scale.
Sources: en.wikipedia.org
centriole A cylindrical organelle composed of microtubules, present only in certain eukaryotes. A pair of centrioles migrate to and define the two opposite poles of a dividing cell where, as part of a centrosome, they initiate the growth of the spindle apparatus.
However, later on, within a more complex cellular environment, these highly hydrophobic LCRs became inappropriate or even toxic from a protein interaction perspective and have been selected against ever since. In addition, they further hypothesize that the very early protopeptides did not have a nucleic acid binding role, because DNA and RNA-binding LCRs are highly enriched in glycine, arginine and lysine, however, arginine and lysine are not among the amino acids of the proposed early genetic code.
The warfare grounded on certain uses of ICTs within an offensive or defensive military strategy endorsed by a state and aiming at the immediate disruption or control of the enemy's resources, and which is waged within the informational environment, with agents and targets ranging both on the physical and non-physical domains and whose level of violence may vary upon circumstances. Robinson et al. proposed in 2015 that the intent of the attacker dictates whether an attack is warfare or not, defining cyber warfare as "the use of cyber attacks with a warfare-like intent." In 2010, the former US National Coordinator for Security, Infrastructure Protection and Counter-terrorism, Richard A. Clarke, defined cyberwarfare as "actions by a nation-state to penetrate another nation's computers or networks for the purposes of causing damage or disruption". The target's own cyber-physical infrastructure may be used by the adversary in case of a cyber conflict, thus weaponizing it.
Sources: en.wikipedia.org
29 September Ekranoplan - the Caspian Sea Monster, about the Caspian Sea Monster and ground-effect vehicles; the US accidentally discovered the Ekranoplan in 1970 by the Defense Intelligence Agency; the vehicle was 300 ft long, and 540 tonnes, and twice as big as the B-52; the Soviets called it a 'prototype ship'; the Alekseyev Central Hydrofoil Design Bureau was in Nizhny Novgorod; Igor Vasilevsky and Vladimir Kirillovikh, the chief designer; the company invented the hydrofoil in the late 1950s, winning the Lenin Prize in 1957; hydroaerodynamics engineer Kirril Rozhdestvensky; Victor Dygalo; construction of the KM began in 1963, first tested in October 1966, flown by Vladimir Loginov, reaching 350 mph; designer Dmitri Sinitsyn; Ivan Kapitanets, and its military version; designer Vladimir Bulanov; Günther Jörg of Germany; the possible Spasatel; the Naval Air Warfare Center at Naval Air Station Patuxent River. Narrated by Heather Couper, produced by Grant McKee, directed by Hamish Barbour, made by Ideal World and the Discovery Channel 6 October Homicide in Kennewick, about Kennewick Man, investigated by Jim Chatters; on 6 July 1996 evidence was found; forensic anthropologist Katie Macmillan; anthropological geneticist David Smith of University of California, Davis; forensic anthropologist Doug Owsley; Stephen McNallen of the Asatru Folk Assembly; Samuel George Morton; the Ainu people of Japan. Produced by Eve Kay, directed by Mark Halliley, made by RDF Television with the Discovery Channel
== Current usage == Many "omes" beyond the original "genome" have become useful and have been widely adopted by research scientists. "Proteomics" has become well-established as a term for studying proteins at a large scale. "Omes" can provide an easy shorthand to encapsulate a field; for example, an interactomics study is clearly recognisable as relating to large-scale analyses of gene-gene, protein-protein, or protein-ligand interactions. Researchers are rapidly taking up omes and omics, as shown by the explosion of the use of these terms in PubMed since the mid-1990s.
Cold fusion is a hypothesized type of nuclear reaction that would occur at, or near, room temperature. It would contrast starkly with the "hot" fusion that is known to take place naturally within stars, artificially in hydrogen bombs, and within prototype fusion reactors; all of which occur at temperatures of millions of degrees. It is also distinguished from muon-catalyzed fusion. There is currently no accepted theoretical model that describes how cold fusion could occur. In 1989, two electrochemists at the University of Utah, Martin Fleischmann and Stanley Pons, reported that their apparatus containing heavy water had produced anomalous heat ("excess heat") of a magnitude they asserted would defy explanation except in terms of nuclear processes. They further reported measuring small amounts of nuclear reaction byproducts, including neutrons and tritium, both of which are produced by fusion of deuterium, found in heavy water (see Fusion power § Deuterium). The small tabletop experiment involved electrolysis of heavy water on the surface of a palladium (Pd) electrode. The reported results received wide media attention and raised hopes of a cheap and abundant source of energy. Both neutrons and tritium are found in trace amounts from natural sources. These traces are produced by cosmic ray interactions and nuclear radioactive decays occurring in the atmosphere and the earth. Many scientists tried to replicate the experiment with the few details available.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.